Abstract:Dendritic cells (DCs) play a crucial role in initiating and shaping immune responses. The effects of DCs on adaptive immune responses depend partly on functional specialization of distinct DC subsets, and partly on the activation state of DCs, which is largely dictated by environmental signals. Fully activated immunostimulatory DCs express high levels of costimulatory molecules, produce pro-inflammatory cytokines, and stimulate T cell proliferation, whereas tolerogenic DCs express low levels of costimulatory molecules, produce immunomodulatory cytokines and impair T cell proliferation. Relevant to the increasing use of immune checkpoint blockade in cancer treatment, signals generated from inhibitory checkpoint molecules on DC surface may also contribute to the inhibitory properties of tolerogenic DCs. Yet, our knowledge on the expression of inhibitory molecules on human DC subsets is fragmentary. Therefore, in this study, we investigated the expression of three immune checkpoints on peripheral blood DC subsets, in basal conditions and upon exposure to pro-inflammatory and anti-inflammatory stimuli, by using a flow cytometric panel that allows a direct comparison of the activatory/inhibitory phenotype of DC-lineage and inflammatory DC subsets. We demonstrated that functionally distinct DC subsets are characterized by differential expression of activatory and inhibitory molecules, and that cDC1s in particular are endowed with a unique immune checkpoint repertoire characterized by high TIM-3 expression, scarce PD-L1 expression and lack of ILT2. Notably, this unique cDC1 repertoire was subverted in a group of patients with myelodysplastic syndromes included in the study. Applied to the characterization of DCs in the tumor microenvironment, this panel has the potential to provide valuable information to be used for investigating the role of DC subsets in cancer, guiding DC-targeting treatments, and possibly identifying predictive biomarkers for clinical response to cancer immunotherapy.

Id2 expression delineates differential checkpoints in the genetic program of CD8α+ and CD103+ dendritic cell lineages.

Regulatory dendritic cells program generation of interleukin-4–producing alternative memory CD4 T cells with suppressive activity

The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets

Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity

Transcriptional regulation of dendritic cell development and function

Cis Interactions Between CD2 and Its Ligands on T Cells Are Required for T Cell Activation

DEC-205 As a Marker of Dendritic Cells with Regulatory Effects on CD8 T Cell Responses.

Distinct ontogenetic lineages dictate cDC2 heterogeneity

Optimization of the Irf8 +32-kb enhancer disrupts dendritic cell lineage segregation

The Closely Related CD103+ Dendritic Cells (DCs) and Lymphoid-Resident CD8+ DCs Differ in Their Inflammatory Functions

Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells

TRIM33 plays a critical role in regulating dendritic cell differentiation and homeostasis by modulating Irf8 and Bcl2l11 transcription

Ly6D+Siglec-H+ precursors contribute to conventional dendritic cells via a Zbtb46+Ly6D+ intermediary stage

Cd4 and Cd8 Expression by Dendritic Cell Subtypes in Mouse Thymus and Spleen

Dendritic cell subsets in T cell programming: location dictates function

Clec12A, CD301b, and FcγRIIB/III define the heterogeneity of murine DC2s and DC3s

Human dendritic cell subsets: an update

Transcriptional control of dendritic cell development and functions

Differential activation profiles of multiple transcription factors during dendritic cell maturation.

A molecular threshold for effector CD8(+) T cell differentiation controlled by transcription factors Blimp-1 and T-bet

Differential Role of Id2 in the Group 3 Innate Lymphoid Cells for the Development of Different Gut Associated Lymphoid Tissues